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Histological prevalence of f2-microglobulin amyloidosis in hemodial-
ysis: A prospective post-mortem study. The histological prevalence of
beta-2 microglobulin amyloidosis (A7m) was evaluated in a prospective
study of joint samples obtained at autopsy in 54 patients on hemodialysis
(HD) for 2 to 163 (median 47) months, aged 20 to 80 (median 63) years
at HD onset. Carpal tunnel syndrome surgery or radiological signs of
A132m were present in 2 and 4% of them, respectively. A control group of
34 patients without end-stage renal disease, autopsied during the same
period was used as a reference. The 153 sampled joints (ito 8, median 2
per patient) were sternoclavicular joints (N 77), shoulders (N = 35),
knees (N = 28), others (N = 13). A32m was diagnosed (positive Congo
red with typical birefringence and positive immunostaining of deposits for
132m) in 26 of 54 (48%) patients. Prevalence reached respectively 21%,
33%, 50%, 90% and 100% within two years, after 2 to 4 years, 4 to 7 years,
7 to 13 years and more than 13 years HD. The calculated sensivity of the
various joints for A132m detection is significantly higher (P < 0.03) for
sternoclavicular joints (97%) and knees (9i%) than for shoulders (57%).
Multivariate stepwise logistic regression with discriminant analysis identi-
fied both HD duration (P = 0.0008) and age at HD Onset (P = 0.0093) hut
not diabetic nephropathy (P = 0.23) or gender (P = 0.25) as independent
risk factors for A2m. The probability of joint A13,m was quantitated as a
function of age and HD duration. In conclusion, A,m may be observed
in the large joints early after HD onset. Overall prevalence reaches 48%
of the patients on HD for a median of 47 months. It is much higher than
that reported on the basis of clinical or radiological evidence. The
sternoclavicular and knee joints are more frequently (P < 0.03) involved
than the shoulder. The easily accessible sternoclavicular joint therefore
appears to be the best site for the early detection of A2m. Both HD
duration and age at HD onset, but not diabetic nephropathy, are
independent risk factors for A2m.
Whereas the prevalence of clinical signs of 2-microglobulin
amyloidosis (A/32m) has been well documented [1—3], the preva-
lence and localization of histological Ap2m remain largely un-
known [4, 5]. We therefore undertook a prospective study of joint
samples obtained at autopsy in 54 hemodialyzed patients. Our
results demonstrate that the prevalence of A2m already reaches
21% within two years after the onset of hemodialysis (HD) and
thereafter rises to exceed 90% beyond seven years of HD.
Prevalence is influenced both by HD duration and by the age of
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the patients at the onset of dialysis, but not by diabetes, a point of
interest as 2m modified with advanced glycation end products
(AGEs) has recently been implicated in the pathogenesis of Ap2m
[6].
Methods
Hemodialysis patients
Inclusion criteria. Participating centers were asked to submit to
post-mortem (unless refused by families) all patients who had
received HD for at least one month and who died either while on
chronic HD, or within less than one month after renal transplan-
tation (TP). Patients treated for more than 10% of total renal
replacement therapy time and/or for more than one year by
another modality [continuous ambulatory peritoneal dialysis
(CAPD), renal TP] were excluded.
Inclusion started in September 1988 in the co-ordinating center
and in July 1992 in the other centers. Samples obtained up to June
30, 1994 were included in this study. Three patients were excluded
as joint samples were inadequate.
Participating nephrologists filled in a form for each patient
that included the following demographics: dates of birth and
death, gender, cause of end-stage renal disease (ESRD), modal-
ities and dates of renal replacement therapy (HD, CAPD, TP),
including dialysis membrane types and duration of their use,
history of carpal tunnel syndrome (CTS) surgery and cause of
death. Whenever available, adequate recent (< 1 year before
death) skeletal X-rays were reviewed by the co-ordinating centre
for evidence of bone signs of Af32m according to previously
defined criteria [1].
Patient characteristics, Fifty-four patients (36 males) were in-
cluded. They had been on HD for 2 to 163 (median 47) months.
The HD membranes used during the main part of HD were AN69
(N = 22), AN69 and high-flux polysulfone (N = 4), cellulose
triacetate (N = 1), cellulose acetate or hemophan (N = 4),
cuprophan (N = 1), hemophan and cuprophan (N = 5), low-flux
polysulforie (N = 1), both high-flux synthetic and low-flux cellu-
losie membranes (N = Ii), and unknown (N = 5).
The age at HD onset ranged from 20 to 80 (median 63) years
and at the time of death from 28 to 82 (median 69) years.
The etiology of ESRD was: chronic interstitial nephropathy
(N = 14), chronic glomerulonephritis (N = 6), nephrosclerosis(N = 12), diabetic nephropathy (N = 9), polycystic kidney disease
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(N = 4), cortical necrosis (N = 1), amyloidosis (N = 2; AA and
AL one each), unknown (N = 6, all non-diabetic patients).
The causes of death were: myocardial infarction (N = 12), heart
failure (N = 11), cerebro-vascular disease (N 3), peripheral
vascular disease (N = 2), ruptured aortic aneurysm (N = I), sepsis
(N = 5), tuberculosis (N = 1), cancer (N = 6: lung, kidney, liver,
pancreas, uterus, esophagus one each), hyperkalemia (N = 2),
various others (N = 6), and unknown (N = 5).
In no case did AJ32m, if present, contribute to or cause death
according to the opinion of the attendant physicians.
Control patients
Thirty-four patients (16 males) without history of ESRD who
died at the coordinating center hospital were randomly selected
and submitted to post-mortem joint sampling. Their ages ranged
from 26 to 88 (median 67) years. The causes of death were: heart
failure (N = 8), cerebro-vascular disease (N = 3), pulmonary
embolism (N = 2), sepsis (N = 4), cancer (N = 5), lymphoma(N = 3), liver failure (N = 2), various others (N = 5), and
unknown (N 2).
Joint samples
The pathologists of participating centres were asked to obtain
at least one large (diameter > 2 cm) non-vertebral joint sample
from all HD patients submitted to post-mortem.
All specimens were fixed in 10% buffered formalin and for-
warded to the co-ordinating center. They were decalcified in 5%
formic acid for one to two weeks, embedded in paraffin, cut and
stained by alkaline Congo red and by the avidin-biotin peroxydase
complex and a monoclonal anti-2m antibody (Dako, Copenha-
gen, Denmark; dilution 1/100) [7, 8].
A total of 153 joint samples were obtained from the 54 HD
patients (range 1 to 8, mean 2.8, median 2 per patient). They
included the sternoclavicular joints (N = 77), the shoulders (N =
35), the knees (N = 28), the hips (N 8), the wrists (N = 4) and
the acromioclavicular joint (N = 1). Sixty joint samples were
obtained from the 34 control subjects (range 1 to 2 per patient).
They included only sternoclavicular joints as these are predomi-
nantly involved in senile amyloidosis [9].
Pathological diagnosis
All slides were reviewed by the same team of pathologists (C.G.
and H.N.), who were blinded to the clinical characteristics of the
patients.
The diagnosis of amyloidosis rested on a positive Congo red
staining with characteristic green-yellow birefringence under po-
larized light.
In all patients with joint amyloidosis, at least one joint sample
was stained by the immunoperoxidase technique with the anti-
132m antibody [7, 8]. A132m was diagnosed when the amyloid
deposits detected by Congo red reacted with the anti-2m anti-
body.
Statistical analysis
Potential risk factors for A/32m (age at HD onset, HD duration,
gender, diabetic nephropathy as the cause of ESRD) were eval-
uated by multivariate stepwise logistic regression with discrimi-
nant analysis [101, using the SPSS statistical package (SPSS mc,
Chicago, IL, USA). Other standard statistical tests were used as
indicated. P values < 0.05 were considered as significant.
Results
Prevalence of A/32m in HD patients
A2m was diagnosed in 26 of 54 (48%) HD patients. The
number of available joint samples was not different in patients
with (median 3) and without (median 2) A!32m (P = 0.11,
Mann-Whitney U-test).
Af32m was detected as early as within 23 months of HD. The
size of Aj32m deposits varied among patients from minute (in the
cartilage) (Fig. 1) to large (involving in the latter case not only
cartilage but also synovium and capsule). The prevalence in-
creased with the duration of HD from 21% within two years to
100% after more than 13 years (Table 1).
Prevalence ofAf32m in control patients
Minute, mainly cartilaginous amyloid deposits were detected in
12 of 34 (35%) patients. They did not react with the anti-132m
antibody. The prevalence of non-J32m amyloid deposits increased
with age: < 55 years: 1+/6 (17%), 55 to 69 years: 4+113 (31%),
70 years: 7+115 (47%) (P < 0.023, Mann-Whitney U-test).
Distribution of A132m in different joints
At least two different joints were available in 24 of the 26
patients with evidence of A2m. The sensitivity of each joint type
for the detection of A/32m was calculated, for the group, as the
ratio of amyloid positive over the total number of each joint type.
Sensitivity was 97% for sternoclavicular joints (37+138), 91% for
knees (13+114) and 57% for shoulders (12+/21) (sternoclavicular
joint vs. knee, NS; sternoclavicular joint vs. shoulder, P =0.0002;
knee vs. shoulder, P = 0.028; Fisher's exact test). The very small
number of samples for hips (3/3) and wrists (1/3) precludes any
conclusion.
Risk factors for the presence of A132m
Multivariate stepwise logistic regression and discriminant anal-
ysis were performed. Multivariate stepwise logistic regression
identified both HD duration (P = 0.0008) and older age at HD
onset (P = 0.0093) as independent, significant risk factors. By
contrast, gender (P = 0.25), diabetic nephropathy as cause of
ESRD (P = 0.23) and the number of available joints (P = 0.77)
were not significant risk factors.
The probability (P) of histological Af32m derived from this
analysis is as follows:
P
1 + ez
with Z = —11.51 + 0.13 age at onset of HD (years) + 0.06
duration of HD (months).
The optimal equation derived by discriminant analysis is Z =
—10,66 + 0.13 age at onset of HD+ 0,06 duration of HD. If Z =
0 is taken as the threshold above or below which A/32m is either
present or absent, this equation correctly classifies 81% (44 of 54)
of our patients. Specificity reaches 96% [1 false (+)128] and
sensitivity 65% [9 false (—)/261 The derived probability of Af32m
as a function of age and HD duration is represented graphically in
Figure 2.
S-. .4
I
—1-—-
U
t_..
-
- -: 6
-
-
,*_.
_t.•_• -
'2
nW. 4 • — ••-Ct' tcaraEeT C... . — ..& . .....r-. I c
Correlation between histological A 2m and CTS or radiological
bone cysts
CTS surgery had been performed in only one patient (2%) and
typical amyloid bone cysts were identified in another one (among
27 patients with adequate recent skeletal X-rays; 4%). Both
patients had histological evidence of Af32m at autopsy.
Discussion
Our study describes for the first time the prevalence of histo-
logical A132m in the large joints in a large series of HD patients.
f32m amyloid deposits are detectable in large joints much earlier
than hitherto accepted: in 21% of the patients within the first two
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Fig. 1. Small /32m amyloid deposits (arrows) on the surface of the stemoclavicular cartilage. No deposits were detected in synovia or capsules in this patient
on HD for 69 months, aged 51 years at HD onset (magnification x550). A. Congo red stain. B. Immunoperoxidase with monoclonal anti-132m antibody.
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HD duration
months
Prevalence of
Af32m
Median age at HD onset
years
1—24 3/14 (21%) 65
25—48 5/15 (33%) 66
49—84 6/12(50%) 59
85—156 9/10 (90%) 57
>156 3/3 (100%) 48
years of HD, in 33% in the subsequent two years, and in over 90%
beyond seven years of HD.
This prevalence is unlikely to exceed that of alive patients
matched for age and HD duration, as A2m never contributed to
death in this study. The prevalence of A2m as a function of the
duration of HD is even probably underestimated: in many of our
patients, A/32m undoubtedly developed months or years before
death.
The actual prevalence of histological A2m was as yet ill
defined. In a recent review, Hakim [5] suspects that it might be
higher than that demonstrated on clinical grounds. In another
review, Koch [41 does not even mention prevalence figures,
presumably because of the paucity of available data and the
conflicting results. In large joints, the reported histological prev-
alence of A132m ranges from 31% [11] to 100% [12, 13]. The
present study casts some light on the reasons for these discrep-
ancies. First of all, A/32m is unevenly distributed among the joints,
as demonstrated in this study by the significantly higher preva-
lence of A/32m in sternoclavicular joints and knees than in
shoulders. Second, within the joints we have observed that A2m
accumulates earlier on the surface of the cartilage than in the
synovia, confirming observations by Athanasou et al [12]. Studies
relying mainly or partly on synovial biopsies are therefore likely to
underestimate prevalence [14, 15]. Furthermore, the conclusion
that AJ32m develops early after the onset of hemodialysis requires
a significant number of early specimens. Until now, observations
were available in only three studies that included 5, 2 and 9
patients who were treated for less than four years, respectively
[11—13], versus 29 in the present study. Finally, the interpretation
of autopsy studies mixing patients treated by both HD and CAPD
[12, 13] and relying on a large range of joint types, including finger
joints, sacro-iliac joints, elbows [11—13] is difficult.
A comparable post-mortem study, limited to the intervertebral
disks of 36 patients on HD for one month to 18 years, has been
reported by Ohashi et al [161. The prevalence of histological
A/32m is close to our estimates in large joints: it rose from none in
14 patients on HD for < 1 year, to 33% in 6 patients on HD for
I to 3 years, 80% in 5 patients on HD for 3 to 5 years and 91% in
ii patients on HD for more than 5 years.
The size of our study allowed for an evaluation of independent
risk factors for A132m. In addition to HD duration we confirm that
age at onset of HD is a significant, independent risk factor for
histological A132m. A similar conclusion had been previously
reported on the basis of clinical [1] and scintigraphic evidence
[17]. A higher prevalence of histological A/32m in older patients
had been suggested in two previous studies, without reaching
statistical significance probably due to the small number of
patients [11, 13].
Why increasing age enhances A/32m deposition remains a moot
point. Sell and Monnier [18] have demonstrated an age-related
increase in the collagen content of pentosidine, an advanced
10 20 30 40 50 60 70 80 90 100 110
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glycoxidation end product (AGE). More recently, Hou et al [191
have provided in vitro evidence that such AGE modified collagen
binds significantly more /32m than normal collagen. It is therefore
possible that an age-related alteration of osteoarticular collagen
results in a preferential binding of /32m. This hypothesis implies a
selective alteration of joint collagen, a still to be demonstrated
phenomenon.
Age is also an important risk factor for non-2m amyloidosis, as
demonstrated in our control group confirming earlier observa-
tions by Goffin, Thoua and Potvliege [9]. The observed prevalence
is lower than that of Af32m and the size of the deposits is markedly
smaller. Still, the detection of non-132m amyloid deposits in ageing
patients at similar locations underlines the importance of a careful
immunohistochemical diagnosis of Ap2m.
The heterogeneity of the types of HD membranes used in our
patients precluded an analysis of membrane type as a risk factor
for Af32m [201.
In contrast with age and duration of HD, logistic regression
failed to identify diabetic nephropathy as an independent risk
factor. This is of interest because patients with diabetic nephro-
pathy have higher levels of AGEs than patients with other causes
of ESRD [21] and because AGE modified /32m has been impli-
cated in A/32m [6]. Our finding requires confirmation in a larger
group of patients and does not exclude the possibility that
diabetes may promote the growth of Af32m deposits, once initi-
ated. Contrary to a recent report [22] we found no effect of gender
on A132m prevalence, confirming a similar conclusion based on
clinical evidence [1].
Our data have allowed us to quantitate the likelihood of
histological A/32m as a function of HD duration and age at onset
of HD. Such a reference frame should prove helpful for the
evaluation of new diagnostic strategies of AJ32m such as scinti-
graphy [23] and ultrasonography [241.
The prevalence of A2m determined on clinical criteria appears
grossly underestimated. In Charra, Calemard and Laurent's large
series [2], CTS required surgery in 0% of patients on HD for eight
years, 50% for 14 years and 100% for 20 years. In contrast,
Table 1. Prevalence of A2m as a function of HD duration
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Fig. 2. Probabiliiy of A/32m as a function of age
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histological Aj32m was found in our study in 50 and 90% of
patients on HD for 4 to 7 and 7 to 11 years, respectively. Similarly,
in the present series, radiological signs of Aj32m also grossly
underestimate (4%) the actual prevalence of the disease, as
detected by histology (48%).
The uneven distribution of Af32m among different peripheral
(non-vertebral) is in agreement with the uneven distribution
already demonstrated by Ohashi et al in the spine, the cervical
segment being more frequently involved than the dorsal segment
[16]. The significantly higher prevalence of Aj32m in the sterno-
clavicular joint suggests that this easily accessible site should be
preferentially investigated in studies concerned with the early
appearance of A/32m. Senile joint amyloidosis in patients without
ESRD is also unevenly distributed, the sternoclavicular joint
being again more frequently involved than the hip joint [9].
Potential explanations include mechanical stress [16], or biochem-
ical characteristics of the respective joints (such as collagen or
glycosaminoglycans composition). Although of interest, the distri-
bution of A/32m among different joints observed in this study
should be interpreted with caution, as this multicenter study did
not sample all joints in all patients. Had this been done, the
reported overall prevalence of Af32m would probably remain the
same as at least one sternoclavicular joint, a very sensitive joint
(97%) for AJ32m detection, was obtained from all A132m(—)
patients except 2 [in one of whom a knee specimen (91%
sensitivity) was available].
In conclusion, A2m may be observed in the large joints early
after the onset of HD. The overall prevalence reaches 48% in
patients on HD for a median of 47 months. Both the HD duration
and age at HD onset (but not diabetic nephropathy as cause of
ESRD) are independent risk factors for A/32m. Their impact on
the probability of Aj32m development is quantified. The preva-
lence of AJ32ni is grossly underestimated by the CTS or radiolog-
ical bone cysts.
Reprint requests to Michel Jadoul, M.D., Cliniques Universitaires St-Luc,
Department of Nephrology, Av. Hippocrate 10, 1200 Bnvcelles, Belgium.
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